Vor Biopharma’s (VOR) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note released on Friday,RTT News reports. The brokerage currently has a $11.00 price objective on the stock.

VOR has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday. Robert W. Baird cut their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday. Barclays cut their target price on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, August 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Friday, September 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vor Biopharma has an average rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Price Performance

VOR opened at $1.01 on Friday. Vor Biopharma has a one year low of $0.63 and a one year high of $3.14. The company’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $1.06. The stock has a market capitalization of $69.08 million, a P/E ratio of -0.61 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting the consensus estimate of ($0.40). As a group, analysts anticipate that Vor Biopharma will post -1.51 EPS for the current year.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rosalind Advisors Inc. acquired a new stake in Vor Biopharma in the 3rd quarter valued at $54,000. Exchange Traded Concepts LLC increased its stake in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after buying an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma in the 2nd quarter valued at $53,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma in the 2nd quarter valued at $63,000. Finally, Hsbc Holdings PLC increased its stake in Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares during the last quarter. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.